Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis
- 20 November 2024 - 1 mins read
This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC). Detailed Description: The primary goal of this study in participants with PSC who are treated with A3907 is to assess the safety and tolerability of A3907 following repeat doses. Secondary goals include evaluation of the pharmacokinetic properties of A3907 (the study of how the body interacts with A3907 for the entire duration of exposure) and changes in safety parameters via laboratory testing such as liver enzymes, bile acid levels and markers of bile acid synthesis.
20 November 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
20 November 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
20 November 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
20 November 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
20 November 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
20 November 2024
1 mins read